NZP’s manufacturing premises are situated on the outskirts of Palmerston North, in the heart of the Manawatu Region of New Zealand. The site is conveniently located near a scientific hub and in close proximity to Massey University which is New Zealand’s largest agri-science University and research base.

New Zealand Pharmaceuticals Ltd was established in 1971 to extract and purify biochemicals from by-products of the New Zealand meat processing industry. The company’s first products were pharmaceutical intermediates extracted from bovine or ovine bile.

NZP’s reputation for quality and service allowed it to become one of the major manufacturers and suppliers of these products worldwide. In 2020 NZP was purchased by ICE Pharma and became a fully integrated part of the group.

NZP has well equipped research laboratories, with two pilot plants for small-scale commercial production, where a dedicated team of scientists work in developing new product opportunities. In the UK R&D centre early-stage research focuses on the synthesis of existing and new bile acids derivatives derived from both animal and plant origin. A library of 500 modified bile acid structures has been developed to screen as potential candidates to treat currently unmet medical needs such as Alzheimer’s and Parkinson’s diseases.

NZP, as part of ICE Group, offer’s a complete solution from proof of concept to full scale commercial cGMP manufacture including.

• Route design
• Process development and optimisation
• Full analytical support
• Process validation
• Technology transfer
• cGMP manufacture

Good Manufacturing Practice (GMP) is an integral part of the company’s culture and ensures that NZP’s products comply with international regulatory requirements. Analytical testing is carried out in-house in well-equipped quality control laboratories staffed by a team of chemists and technicians to ensure high quality products conform to stringent customer specifications. As well as holding a Medicines Licence to manufacture specific products, in addition NZP is GMP certified to manufacture a wider range of products according to the New Zealand code of GMP

NZP is also licensed and audited by the New Zealand Ministry of Primary Industries as a biological processing facility for the manufacture of animal-derived products and hold a medical license for cholic acid and ManNAc.

Safety, Health and Environment (SH&E) is also fundamental to NZP’s values. In 2012, NZP’s Environmental Management System (EMS) was audited against the ISO14001 Standard for the first time and was successful in attaining certification. There is continuous investment at NZP to further improve both safety and the company’s impact on the environment.

The company is also certified by Medsafe for the export of active substances to the EU and has GMP certificates for a number of products.

The companies’ longstanding reputation as a reliable producer of high-quality products is further strengthened by the international recognition of New Zealand’s ‘clean green’ and ‘disease free’ status, remaining free of all class A animal diseases as listed by the OIE.

Environmental Responsibility- In 2012, NZP’s Environmental Management System (EMS) was audited against the ISO14001 Standard for the first time and was successful in attaining certification.
As well as adhering to Legal Requirements, NZP have signed a Memorandum of Partnership with the local Iwi, working together to ensure environmental considerations and concerns relating to regional Māori become part of our decision-making process.

New Zealand Pharmaceuticals is committed to managing Safety, Health and Environment (SH&E) as an integral part of the business. It’s part of their policy to always ensure the integrity of their processes and facilities.